 |
|
A Randomized Trial of Direct-to-Patient Communication to Enhance Adherence to β-Blocker Therapy Following Myocardial Infarction—Invited Commentary
Edward P. Havranek, MD
Arch Intern Med. 2008;168(5):483.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The decline in mortality from cardiovascular disease in the United States over the past 30 years has been due in large part to the steady adoption of new preventive and therapeutic strategies. Over the past 10 to 15 years, there has been increasing recognition that broad adoption of established strategies may have value equivalent to that of the adoption of new strategies. As a result of this recognition, there have been large-scale efforts to improve rates of prescription of proven medications, and these efforts are achieving success.1 On the heels of this success, quality-of-care efforts are evolving further and are beginning to focus on ensuring that patients actually take these proven medications once they have been prescribed.
The study by Smith and colleagues of an intervention to improve β-blocker adherence in this issue of the Archives is thus a welcome addition to the literature. The authors . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLE
A Randomized Trial of Direct-to-Patient Communication to Enhance Adherence to β-Blocker Therapy Following Myocardial Infarction
David H. Smith, Judith M. Kramer, Nancy Perrin, Richard Platt, Douglas W. Roblin, Kimberly Lane, Michael Goodman, Winnie W. Nelson, Xiuhai Yang, and Stephen B. Soumerai
Arch Intern Med. 2008;168(5):477-483.
ABSTRACT
| FULL TEXT
|
